Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04625751 Active, not recruiting - Type 2 Diabetes Clinical Trials

Neurovascular Coupling and Autonomic Neuropathy in Type 2 Diabetes

Start date: April 7, 2021
Phase:
Study type: Observational

Diabetes is a growing global health care challenge. Diabetes patients may also suffer from cardiovascular autonomic neuropathy (CAN) which may affect cerebral perfusion. The main purpose of this project is to investigate the association between CAN and disturbances in the neurovascular coupling in type 2 diabetes patients. Moreover, the purpose is also to investigate coherence between CAN and the enteric nervous system. Finally, this project aims at delineating microstructural changes in the brain tissues as a consequence of CAN.

NCT ID: NCT04625270 Active, not recruiting - Ovarian Cancer Clinical Trials

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

RAMP 201
Start date: December 21, 2020
Phase: Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

NCT ID: NCT04624633 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

This study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL). The names of the study drugs involved in this study are/is: - Acalabrutinib (CALQUENCE®, ACP-196) - Umbralisib (TGR-1202) - Ublituximab (TG-1101)

NCT ID: NCT04624256 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

GARUDA
Start date: November 10, 2020
Phase: N/A
Study type: Interventional

This trial studies the changes in long-term physician-scored genitourinary toxicity achieved in prostate cancer patients eligible for stereotactic radiation therapy when both patients and physicians have access to convincing but non-validated germline signature that can characterize patients as having a low or high risk of developing toxicity after radiation therapy. The information learned from this study may guide patients' and physicians' decisions on radiotherapy fractionation.

NCT ID: NCT04623944 Active, not recruiting - MDS Clinical Trials

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

NCT ID: NCT04623775 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Start date: February 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

NCT ID: NCT04622670 Active, not recruiting - Clinical trials for Cervical Adenocarcinoma

Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer

Start date: March 10, 2020
Phase: N/A
Study type: Interventional

This trial studies how well yoga therapy works during chemotherapy and radiation treatment in improving physical and emotional well-being in patients with stage IB2-IIIB cervical cancer. Yoga therapy may help to balance the mind and body through exercise, meditation (focusing thoughts), and control of breathing and emotions.

NCT ID: NCT04622319 Active, not recruiting - Clinical trials for Residual Invasive Breast Cancer

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Start date: December 4, 2020
Phase: Phase 3
Study type: Interventional

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

NCT ID: NCT04622046 Active, not recruiting - Clinical trials for Symptomatic Transthyretin Amyloid Cardiomyopathy

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Start date: November 13, 2020
Phase: Phase 3
Study type: Interventional

This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.

NCT ID: NCT04621773 Active, not recruiting - Clinical trials for Recurrent Pregnancy Loss

Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

STUDY AIM: to study the pregnancy outcomes and offspring development of patient with Unexplained Recurrent Pregnancy Loss Treated by PGS and spontaneous pregnancy, and to compare the health economic indicators and patient satisfaction of the two modes of pregnancy, so as to better guide the clinical treatment.